Posted by Michael Wonder on 12 Apr 2022
FDA grants Direct Biologics regenerative medicine advanced therapy designation for the use of ExoFlo in COVID-19 related ARDS
12 April 2022 - Direct Biologics announced that the U.S. FDA has awarded their EV drug product ExoFlo with a regenerative medicine advanced therapy designation for the treatment of acute respiratory distress syndrome associated with COVID-19.
ExoFlo is an acellular human bone marrow mesenchymal stem cell derived extracellular vesicle product.
